Sartorius adds chromatography systems and resins, tangential flow filtration, and biomolecular characterization technologies.
Sartorius announced on April 30, 2020 that it closed the acquisition of selected life-science businesses of Danaher Corporation for $825 million and is integrating the acquired laboratory and bioprocessing businesses into two divisions of Sartorius.
The FortéBio label-free biomolecular characterization business includes protein analysis instruments, biosensors, and reagents used for drug discovery and will become part of the Bioanalytics unit within the Sartorius Lab Products & Services Division.
In the bioprocessing area, Sartorius added chromatography systems and resins for downstream processing applications for its Bioprocess Solutions Division.
Brands acquired include Cadence BioSMB PD System, Hillex, HyperCel, HyperD, Resolute chromatography columns, SoloHill microcarriers and particle validation standards, and Ultrogel. The products include reusable and single-use equipment, columns, and resins, as well as stainless-steel hollow fiber and single-use technology tangential flow filtration systems and single-use flow kits.
“The acquisition of this portfolio is a further milestone for Sartorius. The assets we purchased are an excellent strategic and operational fit with both our divisions. We are very pleased to welcome approximately 300 new Sartorius employees and to combine our expertise to become even more relevant together for our biopharma and life science customers,” said Joachim Kreuzburg, Sartorius executive board chairman and CEO in an April 30, 2020 press statement.
Source: Sartorius
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.